Establishment of a Personalized Pharmaceutical Plan in Renal or Hepatic Transplant Patients

Personalized Pharmaceutical Plan After Transpantation Clinical Trial

— GREPH  

Official title:

Mise en Place d'un Plan Pharmaceutique Personnalisé Chez Les Patients transplantés rénaux ou hépatiques : Essai randomisé en Cluster de Type Stepped-wedge.

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04295928
• Other study ID #: DR190061-GREPH
• Secondary ID: 2019-A01723-5492
• Status: Active, not recruiting
• Phase: N/A
• Start date: October 12, 2020
• Est. completion date: September 11, 2025

Study information

• Verified date: November 2022
• Source: University Hospital, Tours
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main objective of the study is to evaluate the impact of the Personalized Pharmaceutical Plan on the therapeutic adherence to immunosuppressive treatments one year after liver or kidney transplantation.

Description:

In 2016, 3,615 renal transplantations (RT) were performed in France. RT is indicated for end-stage renal failure, especially in dialysis patients. The average cost of a year of dialysis is 60,000 €, and that of a kidney transplantation according to the GHS tariff of 20,000 € (excluding preparation of the patient for the transplantation, drugs and post-transplantation follow-up).

In 2016, 1,322 liver transplantations (LT) were performed in France. Indications for LT are mainly acute or chronic hepatic insufficiency and liver tumors. LT is the only therapeutic solution for these patients because there is no such alternative as dialysis in nephrology. According to the DRG (Diagnosis Related Group) tariff, the average cost of a LT is about 35,000€ (excluding preparation for transplantation, drugs and post-transplantation follow-up).

If kidney and liver transplantations allow the patient to return to a life close to normal, with graft survival at one year of 84% for the liver and 91% for the kidney, these is constrained by taking immunosuppressive treatments (IS). In the last few years, progress has been made both in surgery and in immediate post-transplantation management. Therefore, now, the challenges of transplantation lie in the long-term transplant patients management, that is to say in prevention of transplant organ rejection and of anti-rejection drugs side effects (cardiovascular diseases, cancers, infections). This prevention requires optimal adherence of the patients both to the drug treatment and to the hygieno-dietetic rules. The scarcity of grafts in France makes it necessary to maximize graft survival so as to limit the need for a new transplantation.

In the literature, drug adherence of IS is between 45% and 85%. Among the non-adherence factors identified, there is a lack of a therapeutic education program and the delay with respect to the transplantation (with the spacing of the consultations at the hospital).

The investigators hypothesize that the combination of pharmaceutical follow-up during hospitalization, coupled with a strengthened hospital-community link, is central to patient adherence, and therefore to patient and graft survival.

The French Society of Clinical Pharmacy (SFPC) established in 2017 a new model of clinical pharmacy. The latter is based (apart from the regulatory activity of prescriptions analysis), on the implementation of a Personalized Pharmaceutical Plan (PPP) corresponding to a management adapted to the patient's path by proposing best possible medication history, pharmaceutical interviews, dedicated pharmaceutical outpatient consultations and therapeutic education. These actions must be carried out both at the hospital and at the local pharmacy.

Most often, the post-transplantation follow-up is done by the transplant center or for some cases (especially for the liver) by expert centers closer to the patient's home but often quite far from the transplant team. Primary care teams have little or no integration into the care of these patients. This is why the community pharmacist, in collaboration with the transplant team, could be a relay close to the patient ensuring continuity, repetition of messages and follow-up as soon as the post-transplantation consultations spread out.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 1716
• Est. completion date: September 11, 2025
• Est. primary completion date: September 11, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient = 18 years old

• Patient having given his free, informed and express consent

• Patient with a kidney or liver transplantation performed in the 10 participating university hospital centers

• Patient speaking french

• Patient whose main residence is in France and has no project of moving during the study period

• Patient declaring to attend the same pharmacy

• Social insured patient

Exclusion Criteria:

• Patient protected: safeguard of justice, curatorship, tutelage

• Patient having a double liver / kidney transplantation with a center not participating in the study

• Patients with a double organ transplantation kidney /hart

• Patient already transplanted regardless of the organ

Related Conditions & MeSH terms

• Personalized Pharmaceutical Plan After Transpantation

Intervention

Behavioral:
• PPP
Personalized Pharmaceutical Plan on therapeutic adherence to immunosuppressive treatments after the transplantation

Locations

Country	Name	City	State
France	CHU-BREST - Pharmacie clinique La Cavale Blanche	Brest
France	APHM - Service de Pharmacie Clinique; Hôpital de la Timone	Marseille
France	APHM Service Pharmacie- Hôpital de la Conception	Marseille
France	CHU-Montpellier Service Pharmacie Lapeyronie	Montpellier
France	CHU-NANTES Service de Pharmacie	Nantes
France	CHU-POITIERS Service de Pharmacie	Poitiers
France	CHU-REIMS Service de Pharmacie -Robert Debré	Reims
France	CHU-RENNES Pôle Pharmacie, Unité de pharmacie clinique	Rennes
France	CHU-STRASBOURG Service Pharmacie, Hôpital Hautepierre	Strasbourg
France	CHU-TOULOUSE Pôle Pharmacie PURPAN	Toulouse
France	CHU-TOURS Hôpital Bretonneau	Tours
France	CHU-TOURS-Hôpital TROUSSEAU	Tours

Sponsors (3)

Lead Sponsor	Collaborator
University Hospital, Tours	Unité d'Epidémiologie des Données cliniques en Centre-Val de Loire (EpiDcliC), Unité d'Evaluation Médico-Economique (UEME)

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Therapeutic adhesion	The Investigator will consider that a patient is in therapeutic adhesion thanks to two methods : use of the BAASIS® questionnaire (if answer <1 for at least one of the 4 questions in the score, the patient will be considered as a non-adherent) and use of the health insurance data from the national health data system (checking that 100% of the days are covered by possession of immunosuppressive drugs)	1 year after transplantation
Secondary	Drug adherence of all chronic treatments prescribed to the patient (except immunosuppression (IS) drug)	Drug adherence of all chronic treatments prescribed to the patient (except immunosuppression (IS) drug) measured by the EvalObs® scale (graduation from 0 to 15)	1 year after transplantation
Secondary	Knowledge of hygienic-dietetic rules and drug intake modalities	Knowledge of hygienic-dietetic rules and drug intake modalities assessed using an questionnaire ( scale from 1-9)	1 year after transplantation
Secondary	Occurrence of adverse effects	Search for the occurrence of adverse events related to IS (diabetes, hypertension, weight gain, tremor, leukopenia, thrombocytopenia,...) during medical and pharmaceutical consultations.	At month 1,month 3, and 12 months after transplantation
Secondary	Fate of the graft	Study of the fate of the graft (rejection, rejection episodes)	1 year and 3 years after transplantation
Secondary	Assessing patient, medical, and community pharmacist satisfaction	Assessing patient, medical, community pharmacist and trial satisfaction (thanks to a 5-level Likert scale) with the system implemented	1 year after transplantation
Secondary	Assessment of potential release risk by measuring the coefficient of variation (CV) of anticalcineurin doses	A patient with a CV greater than 30% will be considered to be at higher risk of rejection	3 years after transplantation
Secondary	For kidney transplantation : testing for anti-HLA antibodies	Anti-HLA antibodies are known to be responsible for rejection in kidney transplants: search for anti-HLA antibodies directed against the donor one and three years after the transplant by Elisa technique	1 year and 3 years after transplantation
Secondary	Determining the efficiency of the implementation of the PPP	Determining the efficiency of the implementation of this PPP in 3 different ways: by determining the cost per QALY gained at 1 year, the cost per additional patient adherent at 1 year and the cost per first functional graft in additional living patient (living patient, carrying their first graft and functional graft) at 1 year	1 year after transplantation